Summary
Global Markets Direct’s, ‘Lead Discovery Center GmbH - Product Pipeline Review, 2016’, provides an overview of the Lead Discovery Center GmbH’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Lead Discovery Center GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Lead Discovery Center GmbH
- The report provides overview of Lead Discovery Center GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Lead Discovery Center GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Lead Discovery Center GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Lead Discovery Center GmbH’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lead Discovery Center GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lead Discovery Center GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Lead Discovery Center GmbH Snapshot 8
Lead Discovery Center GmbH Overview 8
Key Information 8
Key Facts 8
Lead Discovery Center GmbH - Research and Development Overview 9
Key Therapeutic Areas 9
Lead Discovery Center GmbH - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
Lead Discovery Center GmbH - Pipeline Products Glance 19
Lead Discovery Center GmbH - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Lead Discovery Center GmbH - Drug Profiles 22
Small Molecule for Target RhoGEF12 for Cardiovascular Disease 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Activate Beclin1 for Neurodegenerative Diseases and Viral Infections 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Antagonize RON Kinase for Oncology 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit Cyclophilin for Immunology and Respiratory Disorders 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
englerin A 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule 1 for Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule 2 for Oncology 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule 3 for Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecule 4 for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule for AMD, Inflammation and Oncology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule for Amyotrophic Lateral Sclerosis 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule for Chlamydia Infections 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small molecule for Multiple Sclerosis 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Activate TRIM32 for Neurodegenerative Diseases 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Agonize P2Y6R for Type 2 Diabetes 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Block TRPC4 and TRPC5 for Cardiovascular Disease and Epilepsy 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit AML1/ETO for Acute Myeloid Leukemia 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit CDK12 and CDK13 for Oncology 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Inhibit Chemerin for Inflammation 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Inhibit degS Serine Endoprotease for Bacterial Infections 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Inhibit GLUT1 for Oncology 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule to Inhibit GRK5 for Type 2 Diabetes 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule to Inhibit MARK2 for Alzheimer's Disease 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule to Inhibit RabGGTase for Solid Tumors 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Inhibit SFRP1 for Oncology 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Inhibit Steroid Sulfatase for Oncology 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule to Target Draxin for Oncology 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule to Target Hedgehog Pathway for Oncology 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule to Target K-Ras/PDE Delta for Oncology 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule to Target Nrg1-ErbB4 Pathway for Schizophrenia and Cardiovascular Diseases 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Target SLC6A15 for Major Depressive Disorder 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules 1 for Oncology 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules for Charcot-Marie-Tooth Disease Type I A 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Influenza 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules for Lung Cancer 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules for Oncology 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Activate GFAT for Alzheimer’s Disease 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecules to Inhibit LRRK2 for Parkinson's Disease 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Inhibit NET Formation for Sepsis and SLE 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Target Notch Signaling Pathway for Oncology 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules to Target SIRT7 for Cardiovacular Diseases, Metabolic Syndrome and Oncology 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Lead Discovery Center GmbH - Pipeline Analysis 67
Lead Discovery Center GmbH - Pipeline Products by Target 67
Lead Discovery Center GmbH - Pipeline Products by Molecule Type 69
Lead Discovery Center GmbH - Pipeline Products by Mechanism of Action 70
Lead Discovery Center GmbH - Recent Pipeline Updates 72
Lead Discovery Center GmbH - Dormant Projects 73
Lead Discovery Center GmbH - Locations And Subsidiaries 74
Head Office 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76
List of Tables
Lead Discovery Center GmbH, Key Information 8
Lead Discovery Center GmbH, Key Facts 8
Lead Discovery Center GmbH - Pipeline by Indication, 2016 10
Lead Discovery Center GmbH - Pipeline by Stage of Development, 2016 13
Lead Discovery Center GmbH - Monotherapy Products in Pipeline, 2016 14
Lead Discovery Center GmbH - Partnered Products in Pipeline, 2016 15
Lead Discovery Center GmbH - Partnered Products/ Combination Treatment Modalities, 2016 16
Lead Discovery Center GmbH - Out-Licensed Products in Pipeline, 2016 17
Lead Discovery Center GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016 18
Lead Discovery Center GmbH - Preclinical, 2016 19
Lead Discovery Center GmbH - Discovery, 2016 20
Lead Discovery Center GmbH - Pipeline by Target, 2016 67
Lead Discovery Center GmbH - Pipeline by Molecule Type, 2016 69
Lead Discovery Center GmbH - Pipeline Products by Mechanism of Action, 2016 70
Lead Discovery Center GmbH - Recent Pipeline Updates, 2016 72
Lead Discovery Center GmbH - Dormant Developmental Projects,2016 73
List of Figures
Lead Discovery Center GmbH - Pipeline by Top 10 Indication, 2016 10
Lead Discovery Center GmbH - Pipeline by Stage of Development, 2016 13
Lead Discovery Center GmbH - Monotherapy Products in Pipeline, 2016 14
Lead Discovery Center GmbH - Partnered Products in Pipeline, 2016 15
Lead Discovery Center GmbH - Out-Licensed Products in Pipeline, 2016 17
Lead Discovery Center GmbH - Pipeline by Top 10 Target, 2016 67
Lead Discovery Center GmbH - Pipeline by Molecule Type, 2016 69
Lead Discovery Center GmbH - Pipeline Products by Top 10 Mechanism of Action, 2016 70
